

Adult CIRB - Early Phase Emphasis Meeting Agenda

February 1, 2022

I Continuing Review

10150, A randomized phase 2 study of bevacizumab and either weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or platinum refractory ovarian cancer (Protocol Version Date 07/28/21)

II Continuing Review

10220, A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) Telaglenastat (CB-839) HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors (Protocol Version Date 09/07/21)

III Continuing Review

10346, Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid Tumors (Protocol Version Date 06/01/2021)

IV Continuing Review

CITN-17, Phase 1 Study of NT-I7 (rhIL-7-hyFc) for the Treatment of Kaposi Sarcoma in Patients With or Without Infection with HIV (Protocol Version Date 10/15/21)

V Amendment

10211, A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer (Protocol Version Date 12/20/21)
